We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Agronomics Limited | ANIC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.15 | -1.83% | 8.05 | 10:18:30 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.20 | 8.05 | 8.20 | 8.20 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 27/4/2024 13:00 by 1chrism Link to Anthony Chow investor talk a couple of days agohttps://youtu.be/ |
Posted at 26/4/2024 16:17 by elgordo 2-page cover story ("Tasty Profits - The future of artificial meat") in this week's Moneyweek magazine. A fair summary of the collapse in meat-free alternatives and the long road ahead for cultured meat. Concludes under the sub-head "What to buy" with -"British investors are able to gain access via investment firm Agronomics (Aim: ANIC). The fund spreads the risk across stakes in more than 20 businesses... Yet this is a volatile sector and the shares are off three-quarters since a 2021 high as investors’ enthusiasm diminishes... While performance has been disappointing and the risks are high, the shares are still worth a punt as an opportunity to get in on the ground floor of the food of the future..." |
Posted at 15/4/2024 16:24 by 1chrism Agree and I think that is in fact going to be key for all of ANICs portfolio. BlueNalu is possibly the most advanced with commercial opportunities.There are a couple of key factors to keep in mind with Liberation Labs. Firstly, they are still building the factory and I think may be doing or about to do a fundraiser. Secondly, once they are built if there is a precision fermentation company on the planet that is looking to upscale, they will have no choice but to go to Liberation Labs.Factor one tells us why the share price is and will continue to nose dive and factor two tells us why ANIC are poised to become quite the prospect. I say poised but what I mean is early 2025. Until then, hold off or like bruised investors such as myself look for the bottom then average. They are not going anywhere for at least a decade. |
Posted at 02/4/2024 10:31 by 1chrism Id not heard of ITX before, really interesting company. I see your point and think it does make sense, especially around meat and especially in the US. The declining share price will most definitely have been impacted by the bible belt reaction. Unlike ITX of course, ANIC are not revenue creating at the moment.And in terms of the notion of consumer uptake, ANIC are not reliant on meat and both Mellon and Chow are upfront about the notion that lab meat is a 10 yeqr hence thing. The media just carried away following Good meat and Upside approvals last year.I think that because of interest rates investors are rightly nervous about AIM at the moment and wont care or even notice ANIC until sometime next year when Liberation Labs is operational Meatly have upscalled and they realise BlueNalu works.If you are in ANIC now you are 5 years early to the party |
Posted at 25/3/2024 13:55 by 1chrism I agree that it pays to be diligence and we are investing in a brand new sector. In fact not even new, it is a nascent sector.But I think as you note, what can we actually conclude about the company if/when the share buyback debacle passes? Like you, I dont know and whilst it may irk investors it does not change the status of the companies in their portfolio. Many of which are primed to go commercial in 2025.Then if nothing else ADVFN boards are the place to blow of steam about the companies in which we invest and I am grateful to you for that on this ppint.As a thought, why not submit a Q for the April 23rd Anthony Chow presentation. |
Posted at 25/3/2024 13:39 by quepassa Be careful.The fees levied by Shellbay on ANIC can be very high indeed for such a small fund and can have a big impact on a small balance-sheet either through depletion of cash reserves or significant shareholder dilution. And I don't yet know what to think about those situations where privately held New Agrarian Company Limited (IoM), is a co-investor alongside ANIC in the same company. So when I see a headline RNS announcement about a major Share Buy Back Program which they don't promptly act upon, I don't like it and my antennae start whirring. all imo. dyor. qp |
Posted at 23/3/2024 12:25 by quepassa ...or what might bolster investor confidence in the Company AND THE SHARE-PRICE - is if they pulled the trigger on the October six month Share Buy Back Program which expires in ten days time.the stated intentions of the SBP could not have been clearer. And if there had ever been a time to buy back shares, it has been in the past few weeks when the share price has repeatedly been flirting with multi-year lows since early 2021. In my view, this speaks to the integrity/reliabilit all imo. dyor. qp |
Posted at 09/1/2024 12:42 by quepassa For those who have not yet seen it, the newly launched Agronomics website is very impressive and professional and well worth a visit.A big step forward and first port-of-call for investors and potential investors wanting completely up-to-date info on the Company and the sector. Contains essential information such as full portfolio, detailed Investment case, management bio's and succinct sector information. And don't miss the latest Q4 Corporate presentation to be found on the new Agronomics website under the Investors tab:- hXXps://www.agronomi ALL IMO. DYOR. QP |
Posted at 31/12/2023 14:12 by masurenguy Cellular agriculture can potentially address many of the world’s most pressing problems including greenhouse gas emissions, water pollution & shortages, deforestation, misallocation of land use, ocean health, animal cruelty, antibiotic resistance and climate change. Agronomics is currently the UK’s only listed vehicle providing investors with exposure to a concentrated portfolio investing exclusively in this field. The Company's strategy is to create value for Shareholders through investing in companies that operate in the nascent industry of cellular agriculture, which are environmentally friendly alternatives to the traditional production of meat, fish and plant-based sources.! Agronomics is focused on this industry and has screened over 400 companies, investing only in the most promising start-ups. A massive flow of capital is anticipated to enter the sector in the coming decade led by the necessity to improve supply chain resilience, price stability and nation-states seeking food security. Estimates from Grandview Research and Statista, project the global food system as currently worth over US$ 2 trillion. Annual Report for the Y/E 30 June 2023: Financial Highlights -- Net asset value per share (NAV) at 30 June 2023 of 16.94p (2022: 14.85p), an increase of 14%. -- Net operating profit £25,75m (2022: £12,92m) prior to the Shellbay fee of £ 3,37m (2022: £4,56m) -- Net profit after taxation and the Shellbay fee of £22,37m (2022: £8,36m). -- Investment income, including net unrealised gains, reflected a gain of £ 29,70m (2022: £6,42m). -- The carrying amount of invested assets is £ 141,77m (2022: £94,81m), an increase of 49% -- Cash and cash equivalents and cash deposits stood at £28,09m (2022: £51,48m). -- Total assets of £ 170,20m at 30 June 2023 (2022: £146,39m). -- Total liabilities of £1,94m at 30 June 2023 (2022: £2,48m), including the Shellbay fee of £1,68m. Institutional Shareholders Hargreaves Lansdown (Nominees): 86,746,982. 8.74% BlackRock, Inc: 62,579,338. 6.31% Canaccord Genuity Wealth Management: 57,179,122. 5.76% Interactive Investor Services: 50,792,640. 5.12% JPMorgan Chase Bank: 39,533,515. 3.98% Jupiter Asset Management: 25,371,632. 2.56% Directors Shareholdings Jim Mellon: 152,820,363. 15.40% Richard Reed: 6,354,412. 0.64% David Giampaolo: 2,434,783. 0.25% Denham Eke: 739,390. 0.07% Company Website: Prior thread: ! Flag counter added on 03/03/24 |
Posted at 27/12/2023 08:50 by someuwin 27 December 2023Agronomics Limited ("Agronomics" or the "Company") Annual audited results for the year ending 30 June 2023 Notice of AGM The Board of Agronomics, a leading listed investor in cellular agriculture, is pleased to announce its annual results for the year ending 30 June 2023. Copies of the 2023 Audited Report and Financial Statements are being posted to shareholders and will shortly be available from the Company's website, , in the investor portal section, under the financial reports tab. The Company will post its Notice of Annual General Meeting ("AGM") to Shareholders at the same time. The AGM will be held at the Sanderson Suite, Claremont Hotel, Loch Promenade, Douglas, Isle of Man IM1 2LX at 10:00 a.m. on 8 February 2024. The Board considers it important that all shareholders should have the opportunity to exercise their voting rights at the AGM. To this end, the Company invites shareholders to complete the voting proxy form as early as possible. Shareholders may also submit questions to the Company Secretary either in writing at the registered office or by email to katie@burnbrae.com prior to the meeting and as early as possible. Financial Highlights -- Net asset value per share (NAV) at 30 June 2023 of 16.94 pence (2022: 14.85 pence), an increase of 14%. -- Net operating profit of GBP25,746,348 (2022: GBP12,920,927) prior to accounting for the Shellbay fee due of GBP 3,372,672 (2022: GBP4,562,548) -- Net profit after taxation and the Shellbay fee of GBP 22,373,676 (2022: GBP8,358,379). -- Investment income, including net unrealised gains, reflected a gain of GBP 29,703,324 (2022: GBP6,423,869). -- The carrying amount of invested assets is GBP 141,773,297 (2022: GBP94,813,088), an increase of 49% -- Cash and cash equivalents and cash deposits stood at GBP28,093,984 (2022: GBP51,482,501). -- Total assets of GBP 170,203,091 at 30 June 2023 (2022: GBP146,398,248). -- Total liabilities of GBP1,946 ,093 at 30 June 2023 (2022: GBP2,485,346), including the cash portion of the Shellbay fee due of GBP1,686,336. Operational Highlights -- Led four funding rounds including the Series A round of All G Foods, the Seed round of UK-based fermentation company Clean Food Group, the Seed round of contract manufacturer Liberation Labs, and the seed financing round of HydGene Renewables Pty Ltd's, to engineer microorganisms for hydrogen production. -- In August 2022, Agronomics led All G Food Holding Pty Ltd's (All G Foods) AUD 25 million Series A Round with an AUD 15 million investment. All G Foods is a precision fermentation company based in Australia focusing on the production of sustainable dairy products and proteins. -- In August 2022, Agronomics led Clean Food Group Limited's (Clean Food Group) seed financing with a GBP577,500 investment. Clean Food Group owns intellectual property developed by the University of Bath for a technology platform that produces a bio-equivalent palm oil alternative using microbial fermentation. -- In October 2022, Agronomics announced a US$ 7million additional investment into Liberation Labs Holdings as part of a US$ 20 million Seed financing round. Agronomics precision fermentation contract manufacture portfolio company, Liberation Labs, has made significant progress, including selecting its first site in Richmond, Indiana, US, for its 600,000-litre capacity commercial plant. -- In February 2023, Agronomics announced a US$ 500,000 investment in Wild Microbes Company's (Wild Microbes) US$ 3.3 million pre-seed financing. The company has proprietary technology that allows it to genetically engineer novel microbial strains for use as host organisms to produce proteins and other valuable molecules. -- In June 2023, Agronomics announced a AUD 2.5 million investment in HydGene Renewables Pty Ltd's (HydGene). HydGene engineer's microorganisms act as a proprietary biocatalyst for the production of green hydrogen. The catalyst enables the conversion of waste biomass into gases such as hydrogen and ammonia. Post-period End Highlights -- During the post-period, the United States Department of Agriculture ("USDA") awarded Ameris Bancorp ("Ameris Bank") a US$ 25 million "Business and Industry" loan guarantee to help the continued build and the completion of Liberation Labs manufacturing facility. -- Agronomics invested EUR4 million as part of Meatable's EUR30 million Series B financing round to help further scale Meatable's production processes and accelerate its commercial programme in target markets to deliver cultivated meat products that are price competitive with traditional meat. -- Portfolio company BlueNalu, Inc. raised US$ 33.5 million from new and existing investors in a Series B round. The financing will enable the next stage of BlueNalu's growth and its continued progress towards scaling and commercializing healthy and sustainable seafood in the U.S. and around the world. BlueNalu plans to launch its first commercial product, premium bluefin tuna toro, following regulatory approval. Agronomics has invested, in aggregate, US $8 million across BueNalu's various funding rounds. Jim Mellon, Chairperson of Agronomics Limited, commented: "This financial year has been another strong year of growth for Agronomics and has seen significant progress made across our diverse portfolio within the field of cellular agriculture. We have made investments in new and existing portfolio companies across three main areas; cultivated meat and material, precision fermentation and enabling technologies. Our conservative valuation methodology leads us to believe that there is significant intrinsic value within our portfolio, and we remain well positioned to identify attractive opportunities in the sector. Agronomics has maintained its strong cash position to ensure reserves to support existing portfolio companies where we have high levels of conviction. However, we have also participated in select new deals as investment and commercial progress continues to develop across the sector. We recognise the persistent market turmoil and whilst this reflects the wider macroeconomic environment, we maintain our optimism for the cellular agriculture field. During the year, the industry also made significant progress and saw the first approval of cultivated meat product in the US by the FDA and USDA. This was a landmark event for the field of cultivated meat and moves us further along the path to full scale commercialisation. We look forward to further approvals from within Agronomics' leading portfolio of companies and we expect to start seeing regulatory approvals across our portfolio in major protein categories from 2024. The portfolio continues to show great robustness in the market downturn, as shown by the number of funding rounds that continue to be achieved with uplifts. We have to address the nature of venture capital, and the likelihood of sector consolidation in the near term, as category leaders are identified. We believe our current investment portfolio contains many of these category leaders and shows considerable promise for future growth, particularly given the scale of opportunity for the cellular agriculture sector. The Board will also continue to seek new opportunities in line with its Investing Policy, and we look forward to the future with confidence." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
